glp 1 agonists and depression Insights into a possible role of glucagon-like peptide-1 receptor in the treatment of | Pharmacological Reports A Comprehensive Review of the

2022 Sep;63:101533

Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe Type 2 Diabetes Study

The medicine is being marketed under the brand name Lirafit after receiving approval from the medicine Controller General of India (DCGI)

Long-acting preparations also include semaglutide (SMG), dulaglutide (DUL), long-acting release formulation of exenatide (EX-LAR), and polyethylene glycol loxenatide (PEX-168), which generally need to be injected once a week

Those using GLP-1 RAs achieve clinically meaningful weight loss of between 5 to 24% of their initial body weight, depending on dosing regime and type of drug administered